Bicara Therapeutics Inc. BCAX
8.44 USD -0.68 (-7.46%)
Regular-session close
8.44 0.00 0.00%
After hours · Nov 20, 4:30 PM ET
8.43 Day range 9.14
7.93 52-week range 30.40
- YTD
- -49.85%
- 1 year
- -47.84%
5D -1.31 (-12.88%)
- Market cap
- 560.31M
- EPS (ttm)
- -3.46
- Shares out
- 66.17M
- Forward P/E
- -4.96
- YTD return
- -49.85%
- 1-year return
- -47.84%
- 50-day average
- 20.82
- 200-day average
- 21.33
- Enterprise value
- 621.56M
- Volume
- 814.51K
- Avg volume
- 1.20M
- Open
- 8.83
- Previous close
- 9.12
- Day's range
- 8.43 – 9.14
- 52-week range
- 7.93 – 30.40
- Beta
- -0.69
- Analysts
- Strong Buy
- Price target
- 35.67 (+322.6%)
Key statistics
- Price / book
- 2.46
- Free cash flow
- -76.95M
- Total cash
- 497.26M
- Total debt
- 1.16M
- Return on equity
- -41.01%
- Short % of float
- 22.51%
Fundamental scorecard
3 of 25 checks passed on BCAX’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
BCAX Revenue — quarterly 0
BCAX Net income — quarterly -71.25M
BCAX EPS — quarterly -1.04
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.84 | — | — | — |
| Aug 11, 2026 | Jun 30, 2026 | -0.81978 | -0.82 | 0.00 | -0.03% |
| May 11, 2026 | Mar 31, 2026 | -0.64 | -0.93 | -0.29 | -45.31% |
| Mar 26, 2026 | Dec 31, 2025 | -0.72 | -0.68 | +0.04 | +5.56% |
| Nov 10, 2025 | Sep 30, 2025 | -0.55 | -0.67 | -0.12 | -21.82% |
| Aug 12, 2025 | Jun 30, 2025 | -0.54 | -0.50 | +0.04 | +7.41% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2026 | BTIG | reit | Buy | Buy |
| Aug 19, 2026 | BMO Capital | init | — | Outperform |
| Aug 12, 2026 | Goldman Sachs | main | Neutral | Neutral |
| Aug 12, 2026 | Wedbush | main | Outperform | Outperform |
| Aug 12, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Aug 12, 2026 | Mizuho | main | Neutral | Neutral |
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- bicara.com
News
HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Lowers Price Target to $36
Morgan Stanley Maintains Overweight on Bicara Therapeutics, Lowers Price Target to $30
Stifel Maintains Buy on Bicara Therapeutics, Lowers Price Target to $43
BTIG Maintains Buy on Bicara Therapeutics, Lowers Price Target to $37
Bicara Therapeutics Q3 2026 Earnings Call Transcript Bicara Therapeutics Q3 EPS $(1.04) Misses $(0.81) Estimate
Fabrinet, EverQuote, Lattice Semiconductor, Fiserv And Other Big Stocks Moving Higher On Tuesday Goldman Sachs Downgrades Bicara Therapeutics to Sell, Lowers Price Target to $8
Wedbush Maintains Outperform on Bicara Therapeutics, Lowers Price Target to $24
12 Health Care Stocks Moving In Wednesday's Intraday Session
Your note
Sign in to keep a note on BCAX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COHLHEPP RYAN | Chief Executive Officer | Conversion of Exercise of derivative security | Sep 7, 2026 | 181,641 |
| HYEP IVAN | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 9, 2026 | 129,855 |
| MAZUMDAR CLAIRE | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 9, 2026 | 362,152 |
| MEISNER LARA S. | Officer | Conversion of Exercise of derivative security | Sep 28, 2025 | 0 |
| RA CAPITAL MANAGEMENT, L.P. | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 25, 2026 | 0 |
| RABEN DAVID M.D. | Officer | Conversion of Exercise of derivative security | Apr 26, 2026 | 55,286 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 10.97% | 7,255,993 | 126.83M | Jun 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 9.58% | 6,338,487 | 110.80M | Jun 29, 2026 |
| Siren, L.L.C. | 8.47% | 5,602,970 | 97.94M | Jun 29, 2026 |
| Vestal Point Capital, LP | 7.93% | 5,250,000 | 91.77M | Jun 29, 2026 |
| Deep Track Capital, Lp | 6.20% | 4,100,000 | 71.67M | Jun 29, 2026 |
| Blackrock Inc. | 5.82% | 3,848,090 | 67.26M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 3.29% | 2,179,330 | 38.09M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.53% | 1,676,653 | 29.31M | Jun 29, 2026 |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 1.77% | 1,170,492 | 20.46M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.73% | 1,144,022 | 20.00M | Sep 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.65% | 1,092,258 | 19.09M | Sep 29, 2026 |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 1.52% | 1,004,231 | 17.55M | Jun 29, 2026 |
